Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer.

David J PinatoPetros FessasAlessio Cortellini Lorenza Rimassa

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Combination immunotherapy is an expanding therapeutic modality in hepatocellular carcinoma (HCC), a disease where single-agent immunotherapy has failed to lead to survival benefit. The RESCUE trial adds camrelizumab and apatinib to the therapeutic armamentarium of advanced HCC, raising questions around the optimal positioning of various combination regimens in liver cancer.See related article by Xu et al., p. 1003.

Keyphrases

papillary thyroid
clinical trial
study protocol
phase iii
squamous cell
combination therapy
squamous cell carcinoma
endothelial cells
open label
drug induced